# OnCo record paper-keynote-001-pembrolizumab-nsclc-nejm-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-001-pembrolizumab-nsclc-nejm-2015" ;
  schema:name "KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off"@en ;
  schema:description "The large early trial that showed pembrolizumab shrinks about a fifth of advanced lung cancers, with responses that last, and that identified a PD-L1 score of 50% or more as the group most likely to benefit."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1501824>, <https://clinicaltrials.gov/study/NCT01295827> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1501824> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Garon EB, Rizvi NA, Hui R, et al." ;
  onco:related <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-010-lancet-2016/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/orr/> .